GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AKBA

EFXT

GHRS

MAZE

MCHP

TIGR

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

Eurozone

Commodities

Intraday Update

HCWB

NSSC

TNXP

Crude Oil Moves Higher; Owens &amp; Minor Shares Plummet

Wall Street_Dow

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

GH Research PLC

Biotech

Press Releases

General

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Health Care

Management

GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Financing

GH Research Announces Proposed Public Offering

IPOs

GH Research Announces Pricing of $150 Million Public Offering

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Arvinas

BGM Group

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

Indivior

Innoviva

Maze Therapeutics

Nuvation Bio

Ocular Therapeutix

Omeros

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SIGA Technologies

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Guggenheim

RBC Capital

Stifel

Cantor Fitzgerald

HC Wainwright & Co.

Comments

GH Research

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga